UCLA Well being Jonsson Complete Most cancers Heart researchers and physicians who specialise in treating sufferers with radiation therapies will current knowledge on the most recent radiation oncology analysis and scientific trial outcomes on the 66th annual American Society for Radiation Oncology (ASTRO) assembly in Washington D.C., Sept. 29 to Oct. 2.
The annual assembly, which is the main assembly in radiation oncology, will characteristic 23 abstracts from UCLA investigators that spotlight key areas of radiation oncology, together with new analysis in subspecialties starting from survivorship, lung most cancers/thoracic malignancies, physics, sarcoma, gastrointestinal most cancers, genitourinary most cancers, gynecological most cancers, pediatric most cancers and variety, fairness and inclusion in healthcare.
“Our group is proud to current analysis that pushes the boundaries of what is doable in radiation oncology,” mentioned Dr. Michael Steinberg, professor and chair of Radiation Oncology on the David Geffen Faculty of Drugs at UCLA and director of Scientific Affairs on the UCLA Well being Jonsson Complete Most cancers Heart. “These research, starting from modern approaches in chemoradiotherapy and symptom monitoring to developments in MRI-guided radiotherapy, underscore our dedication to enhancing affected person outcomes and shaping the way forward for most cancers therapy.”
Highlights of noteworthy shows at ASTRO which can be led by UCLA investigators embrace:
Summary 1071: MicroRNA-Primarily based Germline Biomarkers of Pathologic Full Response to Neoadjuvant Chemoradiotherapy in Rectal Most cancers
A group of researchers led by Dr. Joanne Weidhaas, professor of radiation oncology, vice chair of molecular and mobile oncology and director of translational analysis on the David Geffen Faculty of Drugs at UCLA, recognized a genetic signature that might assist predict which sufferers with regionally superior rectal most cancers are more than likely to realize a pathologic full response following therapy with a mixture of chemotherapy and radiotherapy. Previous to this examine, there has not been a molecular based mostly assay to foretell which sufferers are more than likely to learn from chemoradiotherapy to assist with therapy choice. The examine, carried out with 90 sufferers with rectal most cancers, targeted on microRNA-related single nucleotide polymorphisms (miSNPs), that are genetic variations that may disrupt microRNA signaling, a vital course of in regulating gene expression. By analyzing mirSNPs along with scientific variables, together with age, tumor stage and KRAS mutation standing, the researchers developed a predictive mannequin with a robust capability to establish sufferers who would obtain an entire response the place no viable tumor cells stay after therapy. The predictive mannequin, constructed utilizing superior statistical methods, outperformed fashions based mostly solely on scientific elements. This mannequin gives a extra customized strategy that might establish sufferers more than likely to reply to this therapy strategy, and will probably assist them keep away from pointless surgical procedure. The group plans to validate these findings in a bigger affected person cohort and additional examine the mirSNP signature’s capability to foretell therapy toxicity.
Weidhaas will current the findings throughout Session: QP 13-GI 4: GI Cancers: From high to backside on Tuesday, Oct. 1 at 4pm EST in room 152.
Summary 317: Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Physique Radiotherapy for Prostate Most cancers: 2-Yr Outcomes from the MIRAGE Randomized Scientific Trial
In a secondary evaluation of a randomized section 3 scientific trial evaluating two strategies of guiding stereotactic physique radiotherapy (SBRT) for prostate most cancers, researchers discovered sufferers handled with MRI steerage had fewer long-term uncomfortable side effects and higher high quality of life associated to bowel and sexual well being in comparison with these handled with CT steerage. Prostate most cancers is likely one of the most typical cancers amongst males, and radiotherapy is a typical therapy choice, particularly for these with localized illness. Nonetheless, the uncomfortable side effects of therapy could be extreme and long-lasting, affecting a affected person’s urinary, bowel, and sexual operate. The group, led by Dr. Amar Kishan, govt vice chair of radiation oncology on the David Geffen Faculty of Drugs at UCLA, discovered sufferers handled with MRI-guided SBRT skilled considerably fewer grade 2 or increased genitourinary and gastrointestinal poisonous results in comparison with these receiving CT-guided therapy. Particularly, solely 27% of MRI-guided sufferers reported late genitourinary toxicity-;resembling urinary incontinence and irritation-;in comparison with 51% within the CT-guided group. Equally, gastrointestinal toxicity-;resembling bowel issues-;was decreased to only 1.4% with MRI steerage, versus 9% with CT steerage. The examine adopted sufferers for 2 years after therapy, making it probably the most complete evaluations of MRI-guided SBRT to this point.
Kishan will current the findings throughout Session: SS 38-GU 2: Optimizing Therapeutic Ratio in Prostate Most cancers on Tuesday, Oct. 1 at 2:30pm EST in room 202.
Summary 122: Symptom Monitoring with Affected person-Reported Outcomes throughout Definitive Radiation Therapy
On this section 2 examine, led by Dr. Ann Raldow, affiliate professor of radiation oncology on the David Geffen Faculty of Drugs at UCLA, investigators assessed whether or not utilizing a cellular app, referred to as mPROS, to report signs improves the standard of life for sufferers with most cancers present process radiation remedy. Whereas using patient-reported outcomes has proven advantages in enhancing scientific outcomes for sufferers receiving chemotherapy, its results within the context of radiation remedy haven’t been effectively established. This examine sought to fill that hole by evaluating sufferers who used the mPROS app to report signs with these receiving typical care. The examine concerned 59 sufferers receiving definitive radiation remedy alongside chemotherapy for numerous cancers, together with gastrointestinal, gynecological, lung, central nervous system and head and neck cancers. Members had been randomly assigned to both the experimental group, the place they used the mPROS app, or the management group. Sufferers within the experimental group had been inspired to report signs at the very least weekly by way of the app, with extreme or worsening signs mechanically alerting their scientific group. Researchers then measured the influence of this strategy on health-related high quality of life utilizing a validated questionnaire initially, finish and three months after finishing radiation remedy. The outcomes confirmed that there have been no vital variations in bodily or psychological well being outcomes between the 2 teams. Nonetheless, sufferers utilizing the mPROS app expressed excessive satisfaction, feeling extra engaged of their care and discovering the app useful in monitoring their signs. The vast majority of members within the experimental group additionally reported that they might suggest the app to different sufferers.
Raldow will report the findings in Session: SS 04 – PRO/QoL/Survivorship 1: New frontiers in affected person reported outcomes and survivorship on Sunday, Sept. 19 at 3:45pm EST in room 204.